Caricamento...
Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial
AIMS: This two‐part, double‐blind, double‐dummy, randomized, placebo‐controlled trial (83 sites) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed‐dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) who were poorly...
Salvato in:
| Pubblicato in: | Diabetes Obes Metab |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6585831/ https://ncbi.nlm.nih.gov/pubmed/30091172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13496 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|